SG135193A1 - Dosing schedule for erbb2 anticancer agents - Google Patents

Dosing schedule for erbb2 anticancer agents

Info

Publication number
SG135193A1
SG135193A1 SG200706063-5A SG2007060635A SG135193A1 SG 135193 A1 SG135193 A1 SG 135193A1 SG 2007060635 A SG2007060635 A SG 2007060635A SG 135193 A1 SG135193 A1 SG 135193A1
Authority
SG
Singapore
Prior art keywords
erbb2
mammal
directed
inhibitor
anticancer agents
Prior art date
Application number
SG200706063-5A
Other languages
English (en)
Inventor
Samit Kumar Bhattacharya
Richard Damian Connell
James Dale Moyer
Jitesh Pranlal Jani
Dennis Alan Noe
Stefanus Johannes Steyn
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of SG135193A1 publication Critical patent/SG135193A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG200706063-5A 2003-08-18 2004-08-06 Dosing schedule for erbb2 anticancer agents SG135193A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49591903P 2003-08-18 2003-08-18

Publications (1)

Publication Number Publication Date
SG135193A1 true SG135193A1 (en) 2007-09-28

Family

ID=34193358

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200706063-5A SG135193A1 (en) 2003-08-18 2004-08-06 Dosing schedule for erbb2 anticancer agents

Country Status (18)

Country Link
US (1) US20050119288A1 (fr)
EP (1) EP1658080A1 (fr)
JP (1) JP2007502807A (fr)
KR (2) KR20060037447A (fr)
CN (1) CN1838959A (fr)
AR (1) AR045268A1 (fr)
AU (1) AU2004264726A1 (fr)
BR (1) BRPI0413745A (fr)
CA (1) CA2536140A1 (fr)
CO (1) CO5670356A2 (fr)
IL (1) IL173127A0 (fr)
MX (1) MXPA06001989A (fr)
NO (1) NO20061252L (fr)
RU (1) RU2328287C2 (fr)
SG (1) SG135193A1 (fr)
TW (1) TW200522966A (fr)
WO (1) WO2005016347A1 (fr)
ZA (1) ZA200600517B (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1478648B1 (fr) 2002-02-01 2014-04-30 ARIAD Pharmaceuticals, Inc. Composes contenant du phosphore et utilisations associees
TWI229650B (en) * 2002-11-19 2005-03-21 Sharp Kk Substrate accommodating tray
US7501427B2 (en) 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
CN102432552B (zh) 2003-08-14 2016-01-20 阿雷生物药品公司 作为受体酪氨酸激酶抑制剂的喹唑啉类似物
PT1667992E (pt) 2003-09-19 2007-04-30 Astrazeneca Ab Derivados de quinazolina
ME01267B (me) 2004-05-06 2013-06-20 Warner Lambert Co 4-fenilaminokinazolin-6-ilamidi
GB0427131D0 (en) * 2004-12-10 2005-01-12 Glaxosmithkline Biolog Sa Novel combination
US20080194596A1 (en) * 2005-06-03 2008-08-14 Frizer Inc. Therapeutic Combination Including a Selective Erbb2 Inhibitor
CA2609251A1 (fr) * 2005-06-16 2006-12-28 Myriad Genetics, Inc. Compositions pharmaceutiques et leur utilisation
WO2007014335A2 (fr) * 2005-07-27 2007-02-01 The University Of Texas System Combinaisons comportant de la gemcitabine et des inhibiteurs la tyrosine kinase pour le traitement du cancer du pancreas
US8945573B2 (en) 2005-09-08 2015-02-03 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Targeted identification of immunogenic peptides
EP1962839A4 (fr) * 2005-11-14 2010-08-25 Ariad Pharma Inc Administration d'un inhibiteur de mntor pour le traitement des patients atteints du cancer
ES2364901T3 (es) * 2005-11-15 2011-09-16 Array Biopharma, Inc. Procesos e intermedios para la preparación de derivados de n4-fenil-quinazolin-4-amina.
RU2429014C2 (ru) * 2006-03-31 2011-09-20 Массачусетс Инститьют Оф Текнолоджи Лечение опухолей, экспрессирующих мутантные рецепторы egf
CN101415411A (zh) * 2006-04-05 2009-04-22 诺瓦提斯公司 用于治疗癌症的治疗剂组合
CN103330694A (zh) 2006-11-14 2013-10-02 阿里亚德医药股份有限公司 口服制剂
WO2008124824A1 (fr) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Doses et méthodes de traitement du cancer
WO2008124828A1 (fr) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Méthodes de traitement de troubles réagissant à une interruption vasculaire
NZ580869A (en) * 2007-04-10 2011-02-25 Myriad Pharmaceuticals Inc Methods for treating cancer
EP2144504A4 (fr) * 2007-04-10 2012-10-03 Myrexis Inc Méthode de traitement du cancer du cerveau
CA2720983A1 (fr) * 2007-04-10 2008-10-16 Myrexis, Inc. Methode de traitement du melanome
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
ES2417148T3 (es) 2007-06-08 2013-08-06 Genentech, Inc. Marcadores de expresión génica de la resistencia tumoral al tratamiento con inhibidor de HER2
WO2009137714A2 (fr) * 2008-05-07 2009-11-12 Teva Pharmaceutical Industries Ltd. Formes de ditosylate de lapatinib et procédés pour leur préparation
US20100087459A1 (en) * 2008-08-26 2010-04-08 Leonid Metsger Forms of lapatinib compounds and processes for the preparation thereof
TWI461211B (zh) 2009-03-20 2014-11-21 Genentech Inc 抗－ｈｅｒ抗體
EP2793893A4 (fr) 2011-11-23 2015-07-08 Intellikine Llc Régimes de traitement améliorés utilisant des inhibiteurs de mtor
EP3584306A1 (fr) * 2014-01-31 2019-12-25 Toppan Printing Co., Ltd. Kit d'analyse de biomolécule et procédé d'analyse de biomolécule
WO2017075495A1 (fr) * 2015-10-28 2017-05-04 Tarveda Therapeutics, Inc. Conjugués ciblés sstr, et ses particules et formulations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02012870A (es) * 2000-06-22 2003-05-14 Pfizer Prod Inc Derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal.
AU2002339687A1 (en) * 2001-12-12 2003-06-23 Pfizer Products Inc. Quinazoline derivatives for the treatement of abnormal cell growth
UA75482C2 (en) * 2001-12-12 2006-04-17 Pfizer Prod Inc Salts of e-2-methoxy-n-(3-{4-[3-methyl-4-(6-methylpyridine-3-yloxy)phenylamino]quinozaline -6-yl}alyl)acetamide, a method for the preparation and use thereof for the treatment of cancer
EP1567506A4 (fr) * 2002-11-20 2007-06-20 Array Biopharma Inc Cyanoguanidines et cyanoamidines utilisees comme inhibiteurs de erbb2 et egfr
WO2004054585A1 (fr) * 2002-12-18 2004-07-01 Pfizer Products Inc. Derives de 4-anilino quinazoline permettant de traiter une croissance cellulaire anormale

Also Published As

Publication number Publication date
CO5670356A2 (es) 2006-08-31
TW200522966A (en) 2005-07-16
CA2536140A1 (fr) 2005-02-24
CN1838959A (zh) 2006-09-27
AU2004264726A1 (en) 2005-02-24
US20050119288A1 (en) 2005-06-02
BRPI0413745A (pt) 2006-10-24
RU2006102125A (ru) 2007-09-27
MXPA06001989A (es) 2006-05-17
ZA200600517B (en) 2007-02-28
KR20060037447A (ko) 2006-05-03
NO20061252L (no) 2006-05-16
AR045268A1 (es) 2005-10-19
RU2328287C2 (ru) 2008-07-10
JP2007502807A (ja) 2007-02-15
WO2005016347A1 (fr) 2005-02-24
IL173127A0 (en) 2006-06-11
KR20080014144A (ko) 2008-02-13
EP1658080A1 (fr) 2006-05-24

Similar Documents

Publication Publication Date Title
SG135193A1 (en) Dosing schedule for erbb2 anticancer agents
MXPA05003501A (es) Metodos para tratamiento del dolor administrando un antagonista del factor de crecimiento del nervio y un analgesico opioide y composiciones que los contienen.
WO2004043374A3 (fr) Procedes et compositions de traitement du cancer au moyen d'inhibiteurs de la proteasome
GEP20033140B (en) Substituted Bicyclic Derivatives Useful as Anticancer Agents
AU2483000A (en) Treatment of asthma with mek inhibitors
GEP20053424B (en) Pyrimidine-2,4,6-Trione Metalloproteinase Inhibitors
WO2004068931A3 (fr) Anticorps anti-amphireguline (ar) et leur utilisation dans le traitement du cancer et du psoriasis
TW200639159A (en) Treatment of pain
TW200500355A (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
PT1530469E (pt) Forma de dosagem transdérmica que compreende um agente activo, um sal e uma forma de base livre de um antagonista
TR199900827T2 (xx) Siklooksigenaz-2 inhibit�rlerinin neoplazinin tedavisinde ve �nlenmesinde kullan�m�.
WO2004004661A3 (fr) Polytherapie a base de composes de boroproline
HK1091481A1 (en) Therapeutic agents useful for treating pain
WO2005077082A3 (fr) Inhibition d'isoformes de cav3 et variants d'epissage $g(d)25b pour diagnostic et traitement de cancers
AU2009246603A8 (en) Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction
CR20240059A (es) Compuestos tricíclicos como inhibidores de kras.
IL165259A0 (en) Compounds useful in the treatment of anthraxa and inhibiting lethal factor
MX2021010560A (es) Inhibidores de la via il-4/il-13 para una eficacia aumentada en el tratamiento de cancer.
ZA202104960B (en) Methods of treating pain with a thiazoline anti-hyperalgesic
WO2001080813A3 (fr) Methodes de prevention et de traitement de l'alopecie provoquee par la chimiotherapie ou la radiotherapie
TW200503666A (en) Treatment of type 1 diabetes with pde5 inhibitors
DE60325965D1 (de) Für die behandlung bzw. prevention von schmerzen geeignete triazaspiroverbindungen
MX2020007817A (es) Prevención y tratamiento del trastorno del sueño.
GB2426517A (en) Methods and agents for inhibiting dynamin-dependent endocytosis
WO2003079748A3 (fr) Renforcement de therapies cancereuses par inhibition de znf217